Pharmaceuticals News and Research

RSS

Handheld diabetic test from MSGI's Nanobeak

MSGI Security Solutions Inc. (OTCBB: MSGI) today reported that the Company is launching its first product derived from NASA technology, a handheld test for Diabetes, which uses breath instead of blood.

24 Sep 2009

FDA endorses Covidien's REMS program for EXALGO tablets

Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that it presented information to members of a U.S. Food and Drug Administration (FDA) Advisory Committee on the New Drug Application and proposed Risk Evaluation and Mitigation Strategy (REMS) program for EXALGOTM (hydromorphone HCl extended release) tablets, an opioid formulation.

24 Sep 2009

LEO Pharma re-acquires product licensing rights from Warner Chilcott

Warner Chilcott plc (Nasdaq: WCRX) and LEO Pharma announced today that, in exchange for a one-time cash payment of $1.0 billion to Warner Chilcott, LEO Pharma is re-acquiring Warner Chilcott's exclusive product licensing rights in the United States to its topical psoriasis treatments Taclonex(R), Taclonex Scalp(R), Dovonex(R) as well as rights to all products in LEO's development pipeline, and acquiring all inventories of the products.

24 Sep 2009

DATATRAK International signs two clinical studies

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the signing of two worldwide studies exemplifying the versatility of the DATATRAK eClinical platform.

24 Sep 2009

AmeriCares commits to donate medicines and medical supplies to health care organizations

AmeriCares this week pledged to expand its medical assistance across the United States at the 2009 Clinton Global Initiative in New York City. AmeriCares U.S. Medical Assistance Program, announced by President & CEO Curt Welling, is a two-year commitment to improve community health by donating medicines and medical supplies to health care organizations serving the uninsured and underinsured throughout the country.

24 Sep 2009

Advanced Biohealing announces growth strategy to expand its product line

Advanced BioHealing, Inc. (ABH), a leader in commercializing the promise of regenerative medicine, announced a strategic growth plan designed to continue the transformation of this former start-up into the leading international regenerative medicine company.

24 Sep 2009

Safety tips for OTC and prescription medications

The beginning of October marks the start of Talk About Prescriptions Month, which is sponsored by the National Council on Patient Information and Education. In support of this annual awareness effort, Health Net, Inc. (NYSE:HNT) is sharing tips to help consumers safely take over-the-counter (OTC) and prescription medications.

23 Sep 2009

Four percent annual growth for chronic pain drug market

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the chronic pain drug market will experience modest four percent annual growth from 2008 to 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Although the market will increase over the next decade, generic erosion will constrain sales of key branded agents such as Johnson & Johnson's Topamax (topiramate) and Pfizer's Celebrex (celecoxib).

23 Sep 2009

New Fluorescence Molecular Tomography imaging systems from VisEn Medical

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced the launch and availability of a new Fluorescence Molecular Tomography (FMT) imaging system -- the FMT 1500, and an advanced version of its FMT 2500, the FMT 2500 LX.

23 Sep 2009

ART's new generation Optix MX3 optical molecular imaging system unveiled

ART Advanced Research Technologies Inc. ("ART") (TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, today unveiled a new generation of its optical molecular imaging system, called Optix® MX3, at the Industry Workshop opening event of the World Molecular Imaging Congress.

23 Sep 2009

NASDAQ halts trading in CombinatoRx's common stock

CombinatoRx, Incorporated (NASDAQ: CRXX) announced that NASDAQ has halted trading in the Company’s common stock today.

23 Sep 2009

Alimera Sciences starts pilot study of Iluvien intravitreal insert

Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported that enrollment has begun for a pilot study to assess the safety and efficacy of Iluvien(R) in patients with macular edema secondary to retinal vein occlusion.

23 Sep 2009

Clinical informatics solution for health care providers and pharmaceutical firms

Humedica, a next-generation health care informatics company, today announced the company’s official launch, along with the previous completion of its $30 million round of venture capital and the roll-out of its ground-breaking clinical analytics platform.

23 Sep 2009

Cannabis Science to feature in two broadcast radio shows

Cannabis Science Inc. (NASD OTCBB: CBIS) an emerging pharmaceutical cannabis company, is pleased to report that it will be featured on two broadcast radio shows beginning tomorrow with Stu Taylor and the “Equity Strategies Show”. Mr. Taylor will interview Cannabis Science Inc., President & CEO, Dr. Robert Melamede Ph.D., discussing the Company’s strategies with its FDA Drug approval programs, the Company’s progress to date with its critical drug release programs, and future planning for subsequent drug releases through additional Federal and State government agencies.

23 Sep 2009

Phase 2 trial results of Bayer's Nexavar in combination with capecitabine announced

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the full results from their first collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trial showing that Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic agent, capecitabine, significantly extended progression-free survival in patients with advanced breast cancer.

23 Sep 2009

New drug test promises to yield quick and effective response for cancer therapy

A group of scientists from Hamburg may have taken a big step towards more effective cancer drug development, Europe's largest cancer congress, ECCO 15 - ESMO 34 [1], heard today (Wednesday 23 September). Dr Ilona Schonn, Director of Cell Culture Research at Indivumed GmbH, told the conference that they had developed a preclinical drug test platform that would enable researchers to analyse tumour tissue for individual patient drug responses on the molecular level.

23 Sep 2009

Second annual study of FDA drug review released

PAREXEL Consulting, a business unit of PAREXEL International (Nasdaq: PRXL) and a leading global life sciences consultancy serving the biopharmaceutical and medical device industries, today released its second annual study on the state of the U.S. Food and Drug Administration (FDA) drug review process.

From Parexel 23 Sep 2009

Phase 1b interim clinical trial results of IMO-2055, Tarceva and Avast combination announced

Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).

23 Sep 2009

Livingston Securities announces the agenda for the 2nd Annual Livingston Healthcare Summit.

Today, Scott Livingston, CEO and Founder of Livingston Securities (www.livingstonsecurities.com) announced the agenda for the 2nd Annual Livingston Healthcare and Life Science Stakeholders Summit.

23 Sep 2009

New TAXUS Liberté Stent demonstrates superior results for treating long lesions

Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific Corporation (NYSE: BSX), has released comprehensive data from the TAXUS ATLAS clinical program, a series of global, prospective, single-arm trials evaluating the TAXUS(R) Liberté(R) Paclitaxel-Eluting Stent System in a variety of lesions and patient groups. Three-year results from the TAXUS ATLAS Small Vessel and Long Lesion Trials continue to show significant advantages for the newer TAXUS Liberté Stent when compared to the first-generation TAXUS(R) Express(R) Stent.

23 Sep 2009